Shanghai Chest Hospital: Esophageal Squamous Cell Carcinoma trials

The registry lists 15 Esophageal Squamous Cell Carcinoma studies with Shanghai Chest Hospital as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 12Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph NodesNot yet recruitingNCT07830355Phase 2
• Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal CancerRecruitingNCT07811752Phase 2
• Infiltration Pattern of Locally Advanced ESCCEnrolling by invitationNCT07567716
• A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)RecruitingNCT06709417Phase 2
• Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)RecruitingNCT06385730Phase 2
• Neoadjuvant Adebrelimab Plus Chemotherapy for Resectable ESCC: a Single Arm, Prospective Phase 2 Clinical TrialNot yet recruitingNCT06178211Phase 2
• Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal CancerRecruitingNCT06173986Phase 1/2
• Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell CarcinomaRecruitingNCT05978193Phase 2
• Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell CarcinomaRecruitingNCT04135664Phase 3
• Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT）Status unknownNCT05650216Phase 2
• Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant ChemoradiotherapyStatus unknownNCT05103501Phase 2
• Pre-Surgery If Needed for Oesophageal CancerCompletedNCT03937362
• KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT03927495Phase 2
• Apatinib in the Treatment of Recurrence or Metastasis of Esophageal CancerStatus unknownNCT03913182Phase 2
• Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal CancerStatus unknownNCT02938195Phase 2